Valpromide
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
The txgnn-pipeline skill is about pipeline management and doesn't override this report-generation task. I'll proceed with generating the evaluation report directly from the Evidence Pack.
Valpromide: From Anticonvulsant/Mood Disorders to Insomnia
One-Sentence Summary
Valpromide is an amide prodrug of valproic acid, historically associated with anticonvulsant and mood-stabilizing applications — though no approved indication is formally registered in Italy. The TxGNN model predicts it may be effective for insomnia, with 0 clinical trials and 1 publication currently supporting this direction. The overall evidence base remains minimal, placing this candidate at the earliest stage of exploration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No registered indication in Italy (drug not marketed) |
| Predicted New Indication | Insomnia |
| TxGNN Prediction Score | 99.79% |
| Evidence Level | L5 |
| Italy Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for Valpromide. Based on known pharmacological information, Valpromide is a structural amide prodrug of valproic acid — upon metabolism it is converted to valproic acid, which in turn enhances GABAergic neurotransmission in the central nervous system. This mechanism is broadly analogous to that of benzodiazepines, a major class of approved sleep aids, providing a theoretical basis for a sedative/hypnotic effect.
The conceptual link between anticonvulsant/mood-stabilizing drugs and insomnia is not unprecedented: valproate-class agents are sometimes observed to improve sleep architecture as a secondary effect in patients with epilepsy or bipolar disorder. Insomnia frequently co-occurs with agitation and anxiety disorders, and the GABAergic enhancement pathway that underlies Valpromide's anticonvulsant activity could plausibly reduce sleep-onset latency or improve sleep continuity.
However, it is important to emphasise that this mechanistic reasoning is derived indirectly from the valproate class. Valpromide itself has not been directly validated for GABA-mediated sleep promotion in controlled human studies. The TxGNN model prediction (score 99.79%) reflects graph-based biological plausibility, not clinical evidence — and must be interpreted accordingly until prospective data are available.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 10370890 | 1999 | Case Series (n=8) | L'Encephale | Valpromide and carbamazepine used to manage aggressive agitation, anxiety, and insomnia in Alzheimer's dementia patients; both agents showed efficacy with a more favourable side-effect profile than neuroleptics |
Italy Market Information
Valpromide currently holds no marketing authorizations in Italy and is not commercially available on the Italian market.
Safety Considerations
Please refer to the package insert for safety information. No drug interaction data, contraindications, or key warnings could be retrieved for Valpromide at this time.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence supporting Valpromide for insomnia consists of a single 1999 case series (n=8) in which insomnia was a secondary symptom — not a primary endpoint — in a dementia population. There are no registered clinical trials, no regulatory approvals in Italy, and no verified MOA data. The TxGNN score reflects mechanistic plausibility through graph inference, not clinical validation.
To proceed, the following is needed:
- Retrieval and review of the Valpromide package insert (TFDA/EMA sources) to establish key warnings and contraindications before any safety assessment can be conducted
- Confirmation of mechanism of action via DrugBank API query (DG002)
- Prospective pharmacokinetic/pharmacodynamic studies characterising Valpromide's direct CNS sleep-promoting effects independently of valproic acid conversion
- At minimum one Phase 2 exploratory clinical trial in primary insomnia patients (general adult population, not solely dementia cohorts) before upgrading the evidence level
- Assessment of whether Italy/EU regulatory pathway is feasible given zero existing authorizations and no approved indication in any country
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.